154 related articles for article (PubMed ID: 11881607)
1. Accutane risk management program strengthened.
FDA Consum; 2002; 36(1):8. PubMed ID: 11881607
[No Abstract] [Full Text] [Related]
2. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the accutane SMART program.
Brinker A; Kornegay C; Nourjah P
Arch Dermatol; 2005 May; 141(5):563-9. PubMed ID: 15897377
[TBL] [Abstract][Full Text] [Related]
3. The cost of clear skin: balancing the social and safety costs of iPLEDGE with the efficacy of Accutane (isotretinoin).
Doshi A
Seton Hall Law Rev; 2007; 37(2):625-60. PubMed ID: 17294569
[No Abstract] [Full Text] [Related]
4. Accutane-exposed pregnancies--California, 1999.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2000 Jan; 49(2):28-31. PubMed ID: 10680601
[TBL] [Abstract][Full Text] [Related]
5. Continued occurrence of Accutane-exposed pregnancies.
Honein MA; Paulozzi LJ; Erickson JD
Teratology; 2001 Sep; 64(3):142-7. PubMed ID: 11514944
[TBL] [Abstract][Full Text] [Related]
6. A pox on your practice. iPLEDGE program scars dermatologists.
Ortolon K
Tex Med; 2006 May; 102(5):29-31. PubMed ID: 17115578
[No Abstract] [Full Text] [Related]
7. Safe use of acne drug.
FDA Consum; 2005; 39(6):4. PubMed ID: 16669109
[No Abstract] [Full Text] [Related]
8. A risk management program aimed at preventing fetal exposure to isotretinoin: retrospective cohort study.
Cheetham TC; Wagner RA; Chiu G; Day JM; Yoshinaga MA; Wong L
J Am Acad Dermatol; 2006 Sep; 55(3):442-8. PubMed ID: 16908350
[TBL] [Abstract][Full Text] [Related]
9. Update on isotretinoin (Accutane) for acne.
Med Lett Drugs Ther; 1983 Nov; 25(649):105-6. PubMed ID: 6227800
[No Abstract] [Full Text] [Related]
10. Ethical and legal aspects of teratogenic medications: the case of isotretinoin.
Moskop JC; Smith ML; De Ville K
J Clin Ethics; 1997; 8(3):264-78. PubMed ID: 9436085
[No Abstract] [Full Text] [Related]
11. Coping with the isotretinoin registry.
Baldwin HE
Dermatol Ther; 2006; 19(4):241-50. PubMed ID: 17005000
[TBL] [Abstract][Full Text] [Related]
12. Accutane (isotretinoin) revisited: severe birth defects from acne therapy.
Hansen RC
Ariz Med; 1985 Jun; 42(6):363-5. PubMed ID: 3161486
[No Abstract] [Full Text] [Related]
13. FDA ponders approaches to curbing adverse effects of drug used against cystic acne.
Marwick C
JAMA; 1988 Jun; 259(22):3225. PubMed ID: 2967382
[No Abstract] [Full Text] [Related]
14. Acne and accutane.
Burton CS; Eyre RW; Callaway JL
N C Med J; 1984 Aug; 45(8):513. PubMed ID: 6236375
[No Abstract] [Full Text] [Related]
15. US FDA Advisory Committee meetings held to discuss isotretinoin, safety issues and a new accutane formulation.
Maddin S
Skin Therapy Lett; 2000; 6(2):5. PubMed ID: 11071724
[No Abstract] [Full Text] [Related]
16. Adolescents, acne, and the side-effects of Accutane.
Novotny J
Pediatr Nurs; 1989; 15(3):247-8. PubMed ID: 2525246
[TBL] [Abstract][Full Text] [Related]
17. Isotretinoin prescribing: finding a balance between benefit and risk.
Stern RS
Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):611-3. PubMed ID: 16134100
[No Abstract] [Full Text] [Related]
18. What is the best approach to reducing birth defects associated with isotretinoin?
Abroms L; Maibach E; Lyon-Daniel K; Feldman SR
PLoS Med; 2006 Nov; 3(11):e483. PubMed ID: 17121451
[TBL] [Abstract][Full Text] [Related]
19. [Teratogenicity of isotretinoin].
Orfanos CE
Hautarzt; 1984 Oct; 35(10):503-5. PubMed ID: 6238920
[No Abstract] [Full Text] [Related]
20. Acne drug controversy ignites turf battle over prescribing.
Thomas P
Med World News; 1988 Jun; 29(11):46-7. PubMed ID: 10313737
[No Abstract] [Full Text] [Related]
[Next] [New Search]
